Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score

Cancer Medicine

Volumn 5, Issue 1, 2016, Pages 136-141

  Herget, Kimberly A ^a   Patel, Darshan P ^b,c   Hanson, Heidi A ^b,c   Sweeney, Carol ^a,b,c   Lowrance, William t ^b,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Early detection of cancer; Incidence; Prostate specific antigen; Prostatic neoplasms; SEER program; Trends

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ALASKA NATIVE; AMERICAN INDIAN; ARTICLE; ASIAN; BLACK PERSON; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CAUCASIAN; CONTROLLED STUDY; GLEASON SCORE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PACIFIC ISLANDER; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; TREND STUDY; UNITED STATES; CANCER REGISTRY; HEALTH SURVEY; INCIDENCE; PATHOLOGY; PROSTATIC NEOPLASMS;

AGE DISTRIBUTION; HUMANS; INCIDENCE; MALE; NEOPLASM GRADING; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 85006187918     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.549     Document Type: Article

References (23)

1. Siegel, R. L., K. D. Miller, and A. Jemal . 2015. Cancer statistics, 2015. CA Cancer J. Clin. 65:5-29.
2. 2008. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 149:185-191.
3. Schroder, F. H., J. Hugosson, M. J. Roobol, T. L. J. Tammela, S. Ciatto, V. Nelen, et al. 2009. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360:1320-1328.
4. Andriole, G. L., E. D. Crawford, R. L. Grubb III, S.S. Buys, D. Chia, T. R. Church, et al. 2009. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360:1310-1319.
5. Moyer, V. A.; Force USPST. 2012. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157:120-134.
6. Gulati, R., A. Tsodikov, R. Etzioni, R. A. Hunter-Merrill, J. L. Gore, A. B. Mariotto, et al. 2014. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 120:3519-3526.
7. Scosyrev, E., G. Wu, S. Mohile, and E. M. Messing . 2012. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 118:5768-5776.
8. Howlader, N. N. A., M. Krapcho, J. Garshell, D. Miller, S. F. Altekruse, C. L. Kosary, et al., eds. 2015. SEER cancer statistics review, 1975-2012. National Cancer Institute, Bethesda, MD.
9. Ravdin, P. M., K. A. Cronin, N. Howlader, C. D. Berg, R. T. Chlebowski, E. J. Feuer, et al. 2007. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356:1670-1674.
10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEERC.L.*Stat Database. Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (2000-2012) -Linked To County Attributes-Total U.S., 1969-2013 Counties. In: National Cancer Institute DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
11. 2011. Joinpoint Regression Program, Version 3.5.2. Statistical Research and Applications Branch, National Cancer Institute, Bethesda, MD.
12. Kim, H. J., M. P. Fay, E. J. Feuer, and D. N. Midthune . 2000. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19:335-351.
13. Green, F. L., D. L. Page, I. D. Fleming, A. G. Fritz, C. M. Balch, D. G. Haller, et al., eds. 2002. American Joint Committee on cancer staging manual, 6th ed. Springer, New York.
14. Klotz, L., D. Vesprini, P. Sethukavalan, V. Jethava, L. Zhang, S. Jain, et al. 2015. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33:272-277.
15. Howard, D. H. 2012. Declines in prostate cancer incidence after changes in screening recommendations. Arch. Intern. Med. 172:1267-1268.
16. Prasad, S. M., M. W. Drazer, D. Huo, J. C. Hu, and S. E. Eggener . 2012. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 307:1692-1694.
17. Howard, D. H., F. K. Tangka, G. P. Guy, D. U. Ekwueme, and J. Lipscomb . 2013. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff. (Millwood) 32:596-602.
18. Goodwin, J. S., A. Tan, E. Jaramillo, and Y. F. Kuo . 2013. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials. J. Natl. Cancer Inst. 105:743-745.
19. Ross, J. S., R. Wang, J. B. Long, C. P. Gross, and X. Ma . 2012. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch. Intern. Med. 172:1601-1603.
20. Ross, L. E., Y. J. Taylor, L. C. Richardson, and D. L. Howard . 2009. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006. J. Natl. Med. Assoc. 101:316-324.
21. Shao, Y. H., K. Demissie, W. Shih, A. R. Mehta, M. N. Stein, C. B. Roberts, et al. 2009. Contemporary risk profile of prostate cancer in the United States. J. Natl. Cancer Inst. 101:1280-1283.
22. Li, J., Z. Berkowitz, and I. J. Hall . 2015. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations. J. Am. Board Fam. Med. 28:491-493.
23. Barocas, D. A., K. Mallin, A. J. Graves, D. F. Penson, B. Palis, D. P. Winchester, et al. 2015. The effect of the United States Preventive Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US. J. Urol. [Epub ahead of print].